Udayan Guha
Förmögenhet: - $ per 2026-07-31
Förmögenhet: - $ per 2026-07-31
Udayan Guha currently works at NextCure, Inc., as Chief Medical Officer from 2025.
Dr. Guha also formerly worked at TCR² Therapeutics, Inc., as Vice President & Head-Clinical Development from 2022 to 2023.
Dr. Guha received his graduate degree from All India Institute of Medical Sciences and doctorate degree from Albert Einstein College of Medicine, Inc.
| Företag | Datum | Antal aktier | Värdering | Värderingsdatum |
|---|---|---|---|---|
NEXTCURE, INC. -.--% | 2026-04-22 | 0 ( -.--% ) | - $ | 2026-07-31 |
| Företag | Position | Start |
|---|---|---|
| NEXTCURE, INC. | Teknisk/Vetenskaplig/F&U Direktör | 2023-03-01 |
| Företag | Position | Slut |
|---|---|---|
| TCR2 THERAPEUTICS INC. | Företagsledare/Principal | 2023-04-01 |
Aktiva
Inaktiva
Börsnoterade företag
Privata företag
Första gradens relationer
Företag kopplade till första graden
Man
Kvinna
Styrelseledamöter
Chefer
| Privata företag | 4 |
|---|---|
All India Institute of Medical Sciences
All India Institute of Medical Sciences Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Albert Einstein College of Medicine, Inc.
Albert Einstein College of Medicine, Inc. Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
NextCure, Inc.
NextCure, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company which discovers and develops novel immuno medicines to treat cancer & immune related diseases | Health Technology |
TCR2 Therapeutics, Inc.
TCR2 Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage cell therapy company which engages in the development of biological drugs and engineering T-cells for cancer therapy | Health Technology |
Välj din utgåva
All finansiell information anpassad till den nationella nivån